GLP1_NEW

Liraglutide and CPAP injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

CPAPLIRA_SC

Trials: 1
Participants in these arms: 10

Doses in this pooled treatment

Liraglutide and CPAP 3.0 mg injection once daily

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 1.74 (0.09 to 23.95)	0.54
Overweight or obesity without diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 3.94 (0.18 to 74.45)	0.38

Trials

NCT04186494
The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study
2019 · 30 randomized · 24 weeks